ClinicalTrials.gg
RecruitingNCT05783804EAGLEUpdated Oct 2, 2025

Plaque Reversal With Early, Aggressive Lipid Lowering Therapy

An observational study in Coronary Artery Disease Progression, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Observational

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Coronary Artery Disease by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — 5 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

Started
2022
with 2 others
Observational
7 of 11
4 open now
Registered
7th of 11
by date

Among the 11 studies in Coronary Artery Disease by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), this one is one of 3 that started in 2022, is one of 7 observational ones, and was the 7th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 11 studies in Coronary Artery Disease by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Coronary Artery Disease by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), or all of them as a file.
02

Study summary

This study evaluates whether plaques in young patients with familial hypercholesterolemia (aged below 50 years) are susceptible to significant plaque regression with early, intensive lipid lowering therapy.

03

Conditions studied

  • Coronary Artery Disease Progression
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult (newly diagnosed) heterozygous FH patients between 18 and 50 years with non-calcificated plaque on coronary CT angiography and who are not optimally treated yet.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with heterozygous familial hypercholesterolemia
  • Adult between 18 and 50 years old
  • LDL cholesterol levels above 100 mg/dl (>2.6 mmol/L) at inclusion

Exclusion criteria

Exclusion Criteria:

  • Renal insufficiency, defined as \< 30 ml/min
  • History of atherosclerotic cardiovascular events
  • Atrial fibrillation
  • Any other treatment or condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
  • Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Target follow-up
40 Weeks
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. CAD Progression

    Difference in total plaque volume between the initial and follow-up CCTA scan

    Time frame: 40 Weeks

Secondary outcomes

  1. Non-calcified plaque progression

    Difference in non-calcified plaque volume between the baseline and follow-up CCTA scan

    Time frame: 40 Weeks

  2. Calcified plaque progression

    Difference in calcified plaque volume between the baseline and follow-up CCTA scan

    Time frame: 40 Weeks

  3. Number of high-risk plaques

    Difference in number of high-risk plaques between the baseline and follow-up CCTA scan

    Time frame: 40 Weeks

  4. Difference in Pericoronary Adipose Tissue Attenuation

    Difference in Pericoronary Adipose Tissue Attenuation between the baseline and follow-up CCTA scan

    Time frame: 40 Weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Dec 2026, 53 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 53 months is above that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2023
First posted
Mar 24, 2023
StartActual
Jul 7, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Apr 2027
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05783804
Responsible party
E.S.stroes (Prof. dr. E.S.G. Stroes, MD, PhD., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Mar 24, 2023
Start date
Jul 7, 2022
Primary completion
Dec 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Oct 2, 2025

Study contacts

Erik SG Stroes, MD, PhD
Contact
e.s.stroes@amsterdamumc.nl
+205669111
Erik SG Stroes, MD, PhD
principal investigator · Amsterdam UMC, location AMC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion